Personalized Neoantigen-Based Cancer Treatment System
Legal Citation
Summary of the Inventive Concept
A novel, adaptive cancer treatment system utilizing tucaresol analogs, machine learning, and real-time genomic analysis to optimize treatment regimens and improve patient outcomes.
Background and Problem Solved
The original patent relates to compositions containing tucaresol or its analogs for cancer treatment. However, the patent's limitation lies in its focus on fixed compositions and lack of adaptability to individual patient needs. The present inventive concept addresses this limitation by introducing a personalized, adaptive approach to cancer treatment.
Detailed Description of the Inventive Concept
The inventive concept comprises a tucaresol analog library, a neoantigen prediction module, and a machine learning-based treatment optimization engine. The system administers a tucaresol-based composition, monitors tumor response, and dynamically adjusts the composition based on real-time genomic analysis. This enables a highly personalized and effective treatment approach. Additionally, the system can be integrated with nanoparticle delivery systems, bioresponsive linkers, and in-situ generation of tucaresol analogs within the tumor, further enhancing its capabilities.
Novelty and Inventive Step
The new claims introduce a paradigm shift in cancer treatment by integrating machine learning, real-time genomic analysis, and adaptive treatment optimization. This inventive concept is novel and non-obvious compared to the original patent, as it enables a highly personalized and dynamic approach to cancer treatment.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, integration with other omics data, or incorporation of additional treatment modalities. Variations could also include the use of different tucaresol analogs, or the development of new bioresponsive linkers.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the cancer treatment market, with potential applications in personalized medicine, targeted therapies, and precision oncology. The market for cancer treatment is rapidly growing, and this inventive concept is poised to capture a significant share of this market.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K31/192 |
| A | A61 | A61K31/496 |
| A | A61 | A61K39/3955 |
| A | A61 | A61P35/00 |
| C | C07 | C07K16/2818 |
| C | C07 | C07K16/2827 |
| A | A61 | A61K2039/505 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical chemistry, immunotherapy, and computational oncology, with expertise in drug design, immune checkpoint inhibitors, and machine learning-assisted treatment strategies
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with advanced degrees in pharmaceutical sciences, molecular biology, or biomedical engineering, possessing knowledge of cancer immunotherapy, computational biology, and drug development techniques
Obviousness Rationale
A PHOSITA would recognize that the PTD's integration of machine learning, genomic analysis, and adaptive treatment optimization represents a predictable extension of the source patent's foundational work on tucaresol compositions and immune checkpoint inhibitors. The technical variations demonstrate standard approaches in personalized medicine, combining known techniques in computational biology with established pharmaceutical methodologies. The disclosed system builds upon the source patent's core innovations through incremental, technically obvious improvements in treatment personalization and drug delivery.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,522 |
|---|---|
| Title | Compositions containing tucaresol or its analogs |
| Assignee(s) | BeyondSpring Pharmaceuticals, Inc. |